Literature DB >> 15290873

Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+).

Nagavedi S Umapathy1, Vadivel Ganapathy, Malliga E Ganapathy.   

Abstract

PURPOSE: The purpose of this study was to analyze the transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the Na(+)/Cl(-)-coupled amino acid transporter ATB(0,+).
METHODS: The interaction of amino acid esters and valganciclovir with the cloned rat ATB(0,+) was evaluated in a mammalian cell expression system and in the Xenopus oocyte expression system.
RESULTS: In mammalian cells, expression of ATB(0,+) induced glycine uptake. This uptake was inhibited by valine and its methyl, butyl, and benzyl esters. The benzyl esters of other neutral amino acids were also effective inhibitors. Valganciclovir, the valyl ester of ganciclovir, was also found to inhibit ATB(0,+)-mediated glycine uptake competitively. Exposure of ATB(0,+)-expressing oocytes to glycine induced inward currents. Exposure to different valyl esters (methyl, butyl, and benzyl), benzyl esters of various neutral amino acids, and valganciclovir also induced inward currents in these oocytes. The current induced by valganciclovir was saturable with a K0.5 value of 3.1+/-0.7 mM and was obligatorily dependent on Na+ and Cl-. The Na+:Cl-:valganciclovir stoichiometry was 2 or 3:1:1.
CONCLUSIONS: Amino acid esters and the amino-acid-based prodrug valganciclovir are transported by ATB(0,+). This shows that ATB(0,+) can serve as an effective delivery system for amino acid-based prodrugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15290873     DOI: 10.1023/b:pham.0000033019.49737.28

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.580


  16 in total

1.  Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2.

Authors:  M Sugawara; W Huang; Y J Fei; F H Leibach; V Ganapathy; M E Ganapathy
Journal:  J Pharm Sci       Date:  2000-06       Impact factor: 3.534

2.  Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients.

Authors:  M D Pescovitz; J Rabkin; R M Merion; C V Paya; J Pirsch; R B Freeman; J O'Grady; C Robinson; Z To; K Wren; L Banken; W Buhles; F Brown
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Na+- and Cl--coupled active transport of carnitine by the amino acid transporter ATB(0,+) from mouse colon expressed in HRPE cells and Xenopus oocytes.

Authors:  T Nakanishi; T Hatanaka; W Huang; P D Prasad; F H Leibach; M E Ganapathy; V Ganapathy
Journal:  J Physiol       Date:  2001-04-15       Impact factor: 5.182

4.  Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.

Authors:  F Brown; L Banken; K Saywell; I Arum
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

5.  Cloning and functional expression of a human Na(+) and Cl(-)-dependent neutral and cationic amino acid transporter B(0+).

Authors:  J L Sloan; S Mager
Journal:  J Biol Chem       Date:  1999-08-20       Impact factor: 5.157

6.  Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2.

Authors:  K Sawada; T Terada; H Saito; Y Hashimoto; K I Inui
Journal:  J Pharmacol Exp Ther       Date:  1999-11       Impact factor: 4.030

7.  Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea.

Authors:  Banmeet S Anand; Ashim K Mitra
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

8.  Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2.

Authors:  M E Ganapathy; W Huang; H Wang; V Ganapathy; F H Leibach
Journal:  Biochem Biophys Res Commun       Date:  1998-05-19       Impact factor: 3.575

9.  Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys.

Authors:  P de Miranda; T C Burnette
Journal:  Drug Metab Dispos       Date:  1994 Jan-Feb       Impact factor: 3.922

10.  Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery.

Authors:  Takahiro Hatanaka; Masayuki Haramura; You-Jun Fei; Seiji Miyauchi; Christy C Bridges; Preethi S Ganapathy; Sylvia B Smith; Vadivel Ganapathy; Malliga E Ganapathy
Journal:  J Pharmacol Exp Ther       Date:  2003-11-14       Impact factor: 4.030

View more
  17 in total

1.  Immunohistochemical and functional characterization of peptide, organic cation, neutral and basic amino acid, and monocarboxylate drug transporters in human ocular tissues.

Authors:  Rajendra S Kadam; Sunil K Vooturi; Uday B Kompella
Journal:  Drug Metab Dispos       Date:  2012-11-20       Impact factor: 3.922

2.  Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements.

Authors:  Caroline A Larregieu; Leslie Z Benet
Journal:  AAPS J       Date:  2013-01-24       Impact factor: 4.009

3.  The Concise Guide to PHARMACOLOGY 2013/14: transporters.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 4.  The Na+/Cl--Coupled, Broad-Specific, Amino Acid Transporter SLC6A14 (ATB0,+): Emerging Roles in Multiple Diseases and Therapeutic Potential for Treatment and Diagnosis.

Authors:  Mohd Omar F Sikder; Shengping Yang; Vadivel Ganapathy; Yangzom D Bhutia
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

5.  SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer.

Authors:  Senthil Karunakaran; Sabarish Ramachandran; Veena Coothankandaswamy; Selvakumar Elangovan; Ellappan Babu; Sudharsan Periyasamy-Thandavan; Ashish Gurav; Jaya P Gnanaprakasam; Nagendra Singh; Patricia V Schoenlein; Puttur D Prasad; Muthusamy Thangaraju; Vadivel Ganapathy
Journal:  J Biol Chem       Date:  2011-07-19       Impact factor: 5.157

6.  The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.

Authors:  Yasuhiro Tsume; Tuba Incecayir; Xueqin Song; John M Hilfinger; Gordon L Amidon
Journal:  Eur J Pharm Biopharm       Date:  2013-12-19       Impact factor: 5.571

7.  Transporter targeted gatifloxacin prodrugs: synthesis, permeability, and topical ocular delivery.

Authors:  Sunil K Vooturi; Rajendra S Kadam; Uday B Kompella
Journal:  Mol Pharm       Date:  2012-10-11       Impact factor: 4.939

8.  Cloning and functional characterization of the proton-coupled electrogenic folate transporter and analysis of its expression in retinal cell types.

Authors:  Nagavedi S Umapathy; Jaya P Gnana-Prakasam; Pamela M Martin; Barbara Mysona; Ying Dun; Sylvia B Smith; Vadivel Ganapathy; Puttur D Prasad
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-11       Impact factor: 4.799

9.  Human solute carrier SLC6A14 is the beta-alanine carrier.

Authors:  Catriona M H Anderson; Vadivel Ganapathy; David T Thwaites
Journal:  J Physiol       Date:  2008-07-03       Impact factor: 5.182

10.  Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.

Authors:  Yasuhiro Tsume; John M Hilfinger; Gordon L Amidon
Journal:  Mol Pharm       Date:  2008-07-25       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.